Sugi Predict

Sugi Predict / Compounds / SCHEMBL875642

SCHEMBL875642

SCHEMBL875642

COc1ccc(C(=NO)c2ccccc2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MGLL Q99685 1/20 0.60
▸ MAPT P10636 6/20 0.60
▸ HPGD P15428 2/20 0.60
▸ CES2 O00748 1/20 0.60
▸ CES1 P23141 1/20 0.60
▸ POLB P06746 1/20 0.60
▸ XBP1 P17861 1/20 0.60
▸ ALDH1A1 P00352 5/20 0.59
▸ SMN1; SMN2 Q16637 3/20 0.59
▸ GFER P55789 1/20 0.56
▸ MEN1 O00255 2/20 0.51
▸ KMT2A Q03164 2/20 0.51
▸ MAPK1 P28482 2/20 0.51
▸ GAA P10253 1/20 0.51
▸ RAB9A P51151 3/20 0.50
▸ CDK5 Q00535 2/20 0.50
▸ CDK5R1 Q15078 2/20 0.50
▸ NPC1 O15118 2/20 0.50
▸ PKM P14618 1/20 0.50
▸ CA1 P00915 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL244032 0.92 SMN1; SMN2 (0.68) MGLLMAPTHPGDCES2CES1
SCHEMBL28341134 0.82 HPGD (0.68) MGLLMAPTHPGDCES2CES1
SCHEMBL10588485 0.82 KMT2A (0.57) MGLLMAPTHPGDCES2CES1
SCHEMBL27961040 0.80 HPGD (0.64) MGLLMAPTHPGDCES2CES1
SCHEMBL273196 0.80 HPGD (0.64) MGLLMAPTHPGDCES2CES1
SCHEMBL9102 0.79 CES2 (0.69) MAPTHPGDCES2CES1ALDH1A1
SCHEMBL68050 0.79 CES2 (0.69) MAPTHPGDCES2CES1ALDH1A1
SCHEMBL10518077 0.79 CES2 (0.69) MAPTHPGDCES2CES1ALDH1A1
SCHEMBL30741457 0.79 CES2 (0.69) MAPTHPGDCES2CES1ALDH1A1
SCHEMBL68051 0.79 CES2 (0.69) MAPTHPGDCES2CES1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12492225-B2 Melanocyte-regulating peptides IDP DISCOVERY PHARMA, S.L. (ES) 2025-12-09 — — US disclosed
EP-4532513-A1 CYCLIC PEPTIDES WITH ANTIBACTERIAL ACTIVITY AGAINST MULTIDRUG RESISTANT (MDR) PATHOGENS Fundación Privada Instituto De Salud Global Barcelona (ES) 2025-04-09 — — EP disclosed
CN-119451974-A Cyclic peptides having antibacterial activity against Multiple Drug Resistant (MDR) pathogens 巴塞罗那全球健康研究所私人基金会 2025-02-14 — — CN disclosed
US-20240294573-A1 CONSTRAINED PEPTIDES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2024-09-05 — — US disclosed
US-20240083943-A1 VEGF-REGULATING PEPTIDES IDP DISCOVERY PHARMA, S.L. (ES) 2024-03-14 — — US disclosed
WO-2023227771-A1 CYCLIC PEPTIDES WITH ANTIBACTERIAL ACTIVITY AGAINST MULTIDRUG RESISTANT (MDR) PATHOGENS Fundación Privada Instituto De Salud Global Barcelona (ES) 2023-11-30 — — WO disclosed
EP-4271480-A1 VEGF-REGULATING PEPTIDES IDP Discovery Pharma, S.L. (ES) 2023-11-08 — — EP disclosed
CN-116964074-A Peptides that modulate VEGF IDP研发制药有限公司 2023-10-27 — — CN disclosed
CN-111263768-B anticancer peptides IDP研发制药有限公司 2023-10-13 — — CN disclosed
US-20230312649-A1 MELANOCYTE-REGULATING PEPTIDES IDP DISCOVERY PHARMA, S.L. (ES) 2023-10-05 — — US disclosed
CN-1041095-C Steroid compound and pharmaceutical composition for treating prostatic hypertrophy SANKYO CO (JP) 1998-12-09 — — CN disclosed
CN-1195666-A Intermediates of steroids, their preparation and uses SANKYO CO (JP) 1998-10-14 — — CN disclosed
US-5760025-A ADMINISTERING TESTOSTERONE 5A-REDUCTASE INHIBITORS SANKYO COMPANY, LIMITED (JP) 1998-06-02 — — US disclosed
US-5717088-A REACTING WITH A CYANOPHOSPHATE IN THE PRESENCE OF AN ALKALI METAL CYANIDE SANKYO COMPANY, LIMITED (JP) 1998-02-10 — — US disclosed
US-5698720-A INTERMEDIATES FOR TESTOSTERONE 5-ALPHA-REDUCTASE INHIBITORS SANKYO COMPANY, LIMITED (JP) 1997-12-16 — — US disclosed
EP-0567271-B1 Steroid derivatives for the treatment of prostatic hypertrophy, their preparation and uses SANKYO CO (JP) 1997-07-02 — — EP disclosed
EP-0725074-A2 Compounds suitable for use as intermediates in the preparation of Androst-3,5-dien-3-carboxy derivatives SANKYO COMPANY LIMITED (JP) 1996-08-07 — — EP disclosed
US-5536714-A Steroid derivatives for the treatment of prostatic hypertrophy their preparation and uses SANKYO COMPANY, LIMITED (JP) 1996-07-16 — — US disclosed
CN-1083070-A Steroid derivatives for the treatment of prostatic hypertrophy, process for their preparation and their use SANKYO CO (JP) 1994-03-02 — — CN disclosed
EP-0567271-A2 Steroid derivatives for the treatment of prostatic hypertrophy, their preparation and uses SANKYO COMPANY LIMITED (JP) 1993-10-27 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12492225-B2 Melanocyte-regulating peptides MC1R, MITF, MCHR1 MGLL 4256/4885MAPT 4183/4885HPGD 3375/4885
US-20240294573-A1 CONSTRAINED PEPTIDES IAPP, NGLY1, VIP MGLL 2411/4885MAPT 2443/4885HPGD 3728/4885
US-20240083943-A1 VEGF-REGULATING PEPTIDES VEGFA, FLT4, FLT1 MGLL 4882/4885MAPT 1972/4885HPGD 3358/4885
US-20230312649-A1 MELANOCYTE-REGULATING PEPTIDES MC1R, MITF, MCHR1 MGLL 4119/4885MAPT 3991/4885HPGD 3313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.